Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
News & Analysis: Aimmune Therapeutics
Is this battered biotech stock now a good deal for investors?
AIMT earnings call for the period ending June 30, 2020.
These under-the-radar names pack some huge growth potential.
Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around?
Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.
AIMT earnings call for the period ending March 31, 2020.
A recent drug approval, a competitor's setback, and a discounted stock price make Aimmune an intriguing investment.
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.